<SEC-DOCUMENT>0000950103-18-003175.txt : 20180308
<SEC-HEADER>0000950103-18-003175.hdr.sgml : 20180308
<ACCEPTANCE-DATETIME>20180308161716
ACCESSION NUMBER:		0000950103-18-003175
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180308
FILED AS OF DATE:		20180308
DATE AS OF CHANGE:		20180308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		18676665

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp87848_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.65pt; text-align: center"><FONT STYLE="font-size: 10pt">UNITED
STATES&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 154pt; text-align: center"><FONT STYLE="font-size: 10pt">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 154pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.85pt; text-align: center"><FONT STYLE="font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.85pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.8pt; text-align: center"><FONT STYLE="font-size: 10pt">__________________</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.8pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.45pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.45pt; text-align: center"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">__________________</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.95pt; text-indent: 15.75pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 190.1pt 0pt 190.7pt; text-align: center; text-indent: -0.7pt"><FONT STYLE="font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 190.1pt 0pt 190.7pt; text-align: center; text-indent: -0.7pt"><FONT STYLE="font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16 of</FONT></P>

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 190.1pt 0pt 190.7pt; text-align: center; text-indent: -0.7pt"><FONT STYLE="font-size: 10pt">the
Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 190.1pt 0pt 190.7pt; text-align: center; text-indent: -0.7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 194.55pt 0pt 194.5pt; text-align: center; text-indent: 0.75pt"><FONT STYLE="font-size: 10pt">March
8, 2018</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 194.55pt 0pt 194.5pt; text-align: center; text-indent: 0.75pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 194.55pt 0pt 194.5pt; text-align: center; text-indent: 0.75pt"><FONT STYLE="font-size: 10pt">Commission
File Number: 001-38283</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 194.55pt 0pt 194.5pt; text-align: center; text-indent: 0.75pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.8pt; text-align: center"><FONT STYLE="font-size: 10pt">__________________________________</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.8pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>InflaRx
N.V.</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.75pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.8pt; text-align: center"><FONT STYLE="font-size: 10pt">__________________________________</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.8pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Winzerlaer
Str. 2</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>07745
Jena, Germany</B></FONT>&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(+49)
3641 508180</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 209pt 0pt 208.85pt; text-align: center"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.35pt 0pt 154pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address
of principal executive offices)</FONT>&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.8pt; text-align: center"><FONT STYLE="font-size: 10pt">__________________________________</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.5pt 0pt 153.8pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">Indicate by check mark
whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.4pt 0pt 154pt; text-align: center"><FONT STYLE="font-size: 10pt">Form
20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 153.4pt 0pt 154pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><FONT STYLE="font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal">On March 8, 2018,
InflaRx N.V. (&ldquo;InflaRx&rdquo;) issued a press release announcing enrollment of the first patient in its Phase IIb study with
its lead product candidate IFX-1 in patients suffering from moderate or severe Hidradenitis Suppurativa. The randomized, double-blind,
placebo-controlled, multicenter study will be conducted in approximately 50 sites in several countries. Approximately 175 patients
will be enrolled in five dose groups. After a placebo-controlled, double-blind period of 16 weeks, the study will be extended to
a 28-week open-label extension phase to assess long-term efficacy and safety. The main objective of the study is the evaluation
of a dose response signal, assessed by the Hidradenitis Suppurativa Clinical Response (HiSCR) score at week 16 as the primary endpoint.
Additional objectives include the evaluation of safety and tolerability of IFX-1 as well as an assessment of additional efficacy
and patient-reported outcome parameters. A copy of this press release is attached hereto as Exhibit 99.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">INCORPORATION BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-weight: normal">Exhibit 99.1 to this
Report on Form 6-K shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934 (the
&ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt; font-weight: normal"></FONT></P>

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">SIGNATURES</FONT></P>

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 18.05pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Jena, Germany, March 8, 2018.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 18.05pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 18.05pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">INFLARX N.V.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 58%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Niels Riedemann</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Niels Riedemann</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
</TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 18.05pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 244pt; text-indent: 20.2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT
INDEX</FONT></P>

<P STYLE="font: bold 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</FONT></TD>
    <TD STYLE="width: 89%; border-bottom: black 1pt solid; font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Exhibit</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 11pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx N.V. Press Release
    dated March 8, 2018</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp87848_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">InflaRx
announces first patient enrolled in Phase IIb trial<BR>
with lead candidate IFX-1 in Hidradenitis Suppurativa</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>Jena,
Germany, March <FONT STYLE="background-color: White">8</FONT>, 2018 &ndash; InflaRx N.V. </B>(Nasdaq:IFRX), the biopharmaceutical
company developing new therapeutics in the terminal complement space, today announced enrollment of the first patient in its Phase
IIb study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients suffering from moderate or severe
Hidradenitis Suppurativa (HS). HS is a painful, chronic and debilitating inflammatory skin disease with limited treatment options.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The
randomized, double-blind, placebo-controlled, multicenter study will be conducted in approximately 50 sites in several countries,
including the United States, Germany, Greece, Denmark and the Netherlands. Approximately 175 patients will be enrolled in five
dose groups. After a placebo-controlled, double-blind period of 16 weeks, the study will be extended to a 28-week open-label extension
phase to assess long-term efficacy and safety. The main objective of the study is the evaluation of a dose response signal, assessed
by the Hidradenitis Suppurativa Clinical Response (HiSCR) score at week&nbsp;16 as the primary endpoint. Additional objectives
include the evaluation of safety and tolerability of IFX-1 as well as an assessment of additional efficacy and patient-reported
outcome parameters.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Othmar
Zenker, M.D., Chief Medical Officer of InflaRx, said: &ldquo;We are very pleased to start our first Phase IIb trial with our lead
candidate IFX-1. After the very promising results from a Phase IIa trial, with this study we aim to determine the optimal dose
regimen as well as to assess the long-term efficacy and safety of IFX-1.&rdquo;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Prof.
Dr. med. Evangelos J. Giamarellos-Bourboulis, of the ATTIKON University Hospital in Athens, Greece, the principal investigator
of this trial, said: &ldquo;New treatment options for moderate to severe HS are of immense importance to patients and clinicians
as the current treatment options for many patients with HS are limited. The C5a blockade with IFX-1 offers an entirely new mode
of action to tackle this disease. The trial design is based on the exciting results from the previously conducted Phase IIa study.&rdquo;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif"></FONT>&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B>About
IFX-1:</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">IFX-1
is a first-in-class monoclonal anti-complement factor C5a antibody which highly effectively blocks the biological activity of
C5a and demonstrates high selectivity towards its</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">target in
human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism,
which is not the case for molecules blocking the cleavage of C5. IFX-1 has demonstrated control of the inflammatory response driven
tissue and organ damage by specifically blocking C5a as a key &ldquo;amplifier&rdquo; of this response in pre-clinical studies.
IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development and has, to date, successfully completed
three clinical Phase II studies. In total, over 150 patients have so far been treated with IFX-1, which was well tolerated. IFX-1
is currently being developed for different inflammatory indications.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About
InflaRx N.V.:</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">InflaRx (Nasdaq:IFRX)
is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop
first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression
of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich,
Germany. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol &ldquo;IFRX&rdquo;.
For further information please visit <FONT STYLE="color: blue"><U>www.inflarx.com</U></FONT>.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>InflaRx
N.V.</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Prof. Dr.
Niels C. Riedemann - CEO</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Email: <FONT STYLE="color: blue"><U>info[at]inflarx.de</U></FONT></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tel: +49-3641-508180</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>MC Services
AG</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Katja Arnold,
Andreas Jungfer</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Email: <FONT STYLE="color: blue"><U>inflarx[at]mc-services.eu</U></FONT></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tel: +49-89-210
2280</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>FORWARD
LOOKING STATEMENTS </B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This press
release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements,
which are often indicated by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue&rdquo;
and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements
regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our
ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and
obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop
commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect
the industry or us and the risks uncertainties and other factors described under the heading &ldquo;Risk Factors&rdquo; in InflaRx&rsquo;s
periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release
and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
statements.&nbsp; Given these risks, uncertainties and other factors, you should not place undue</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">reliance on these forward-looking statements,
and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future,
except as required by law.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O )<# 2(  A$! Q$!_\0
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MYH YOPYH/]OWDMOYYA6*/>6V;N^ ,9^OY5WMOIB>%?"M^BS^:0LDN_;MY*X
MQ^ K*^'-OBWO[DC[SK&#]!D_SK5\<7'D>&)D'69TC_7)_04 <CX"MO-\1B3M
M!"S?B<+_ %-2>*/$%SK.I'3;%F^S!_*5$/,SYQS[9Z#\:E\'YM=%US45X>.'
M:A]PI/\ 452\#P+-XGA+C/E1NXSZXQ_6@1>O?!,>F:!/?75XYN(H]VR-1LSV
M'/)Y[U'\/K82Z]-.1_J8#@^[$#^0-;'Q!U)8M/ATY&_>3,'<#L@_Q./R-5?
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(0!1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
